{"nctId":"NCT01869491","briefTitle":"Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study","startDateStruct":{"date":"2013-06-05","type":"ACTUAL"},"conditions":["Gastroesophageal Reflux Disease","Dyspepsia"],"count":1107,"armGroups":[{"label":"Sodium Alginate Double Action Chewable Tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Compound Sodium Alginate Double Action Chewable Tablets"]},{"label":"Matching placebo tablets","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching placebo tablets"]}],"interventions":[{"name":"Compound Sodium Alginate Double Action Chewable Tablets","otherNames":["Gaviscon Double Action Tablets"]},{"name":"Matching placebo tablets","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current evidence of symptomatic GERD in accord with the Montreal definition.\n* Patients must have had troublesome heartburn and/or regurgitation (with or without dyspepsia symptoms) of at least mild or moderate intensity on at least 5 days during the week before the start of screening.\n\nExclusion Criteria:\n\n* Patients who have a history of drug, solvent or alcohol abuse.\n* Patients who have suffered cardiac chest pain within the last year.\n* Patients who have suffered a recent, significant unexplained weight loss of more than 6 kg in the last 6 months.\n* Female patients of childbearing potential who, for the duration of the study, are either unwilling or unable to take adequate contraceptive precautions or are unwilling to be sexually abstinent.\n* Pregnancy or lactating mother.\n* Patients with a history and/or symptom profile suggestive of the following: any other gastrointestinal (GI) disease, erosive GERD (Los Angeles classification grades C-D), Barrett's oesophagus, acute peptic ulcer and/or ulcer complications, Zollinger-Ellison syndrome, gastric carcinoma, pyloric stenosis, oesophageal or gastric surgery, intestinal obstruction, current pernicious anaemia, indication for H. pylori eradication therapy, known gastrointestinal bleeding (hematochezia or hematemesis) within 3 months prior to the study, and severe diseases of other major body systems.\n* Patients who were observed at screening to have a hiatus hernia with a diameter which exceeds 3 cm.\n* Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for treating gastrointestinal disease, ulcermin or misoprostol preparations within 7 days prior to screening or throughout the study.\n* Patients who have taken proton pump inhibitors (PPIs) during the 10 days prior to screening, prokinetics or H2 antagonists during the 5 days prior to screening or systemic glucocorticosteroids, non-steroidal anti-inflammatory drugs (except for low dose aspirin which can be given for cardioprotection) on more than 3 consecutive days or PPI-based triple or quadruple therapy for eradication of H-pylori during the last 28 days.\n* Patients taking or requiring to take macrolide antibiotics, such as erythromycin, azithromycin, from the day before screening.\n* Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.\n* Patients with severe constipation, or history of intestinal obstruction.\n* In the opinion of the Investigator, patients with damaged heart or kidney function and patients who require a low sodium diet.\n* Any previous history of allergy or known intolerance to any of the investigational medicinal products.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Reflux Disease Questionnaire (RDQ) Scores for the GERD Dimension","description":"The primary study endpoint is the change from baseline in RDQ symptom scores for the GERD dimension (heartburn and regurgitation) after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo. The RDQ is a 12-item self-administered questionnaire designed to assess the frequency and severity of heartburn, acid regurgitation and dyspepsia symptoms, with a minimum score of 0 and a maximum score of 60, with lower RDQ scores showing an improved outcome. The heartburn and acid regurgitation subscales can be combined into a GERD dimension, which has a minimum score of 0 and a maximum score of 40, with lower RDQ scores showing an improved outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":null},{"groupId":"OG001","value":"-1.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in RDQ Scores for the Dyspepsia Dimension","description":"The change from baseline in RDQ symptom scores for the dyspepsia dimension after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo. The dyspepsia subscale of the RDQ has a minimum score of 0 and a maximum score of 20, with lower RDQ scores showing an improved outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":null},{"groupId":"OG001","value":"-0.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in RDQ Scores for the Heartburn Dimension","description":"The change from baseline in RDQ symptom scores for the heartburn dimension after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo. The heartburn subscale of the RDQ has a minimum score of 0 and a maximum score of 20, with lower RDQ scores showing an improved outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":null},{"groupId":"OG001","value":"-0.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in RDQ Scores for the Regurgitation Dimension","description":"The change from baseline in RDQ symptom scores for the regurgitation dimension after a 7-day treatment period of Compound Sodium Alginate Double Action Chewable Tablets compared with a matched placebo. The regurgitation subscale of the RDQ has a minimum score of 0 and a maximum score of 20, with lower RDQ scores showing an improved outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":null},{"groupId":"OG001","value":"-1.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Treatment Evaluation (OTE) as a Measure of Patient Responsiveness/Satisfaction: Question 1 - Patient's Evaluation of the Change in Symptoms Over the Last 7 Days","description":"Comparison between the 2 cohorts (Compound Sodium Alginate Double Action Chewable Tablets and matching placebo) in OTE as a measure for patient's responsiveness/satisfaction, determined at Visit 3, the end-of-study visit.\n\nQuestion 1 of the OTE assessed how the patients rated their responsiveness/satisfaction on a 15-point scale (from -7 = a very great deal worse to +7 = a very great deal better).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"64","spread":null}]},{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"47","spread":null}]},{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"106","spread":null}]},{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"89","spread":null}]},{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"72","spread":null}]},{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"92","spread":null}]},{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"33","spread":null}]},{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"OTE as a Measure of Patient Responsiveness/Satisfaction: Question 2 - Patient's Evaluation of the Importance of the Change in Symptoms","description":"Comparison between the 2 cohorts (Compound Sodium Alginate Double Action Chewable Tablets and matching placebo) in OTE as a measure for patient's responsiveness/satisfaction, determined at Visit 3, the end-of-study visit.\n\nQuestion 2 of the OTE addressed how patients perceived the importance of the change of the clinical status on a 7-point scale (from 1 = not important to 7 = extremely important).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"51","spread":null}]},{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"44","spread":null}]},{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"49","spread":null}]},{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"153","spread":null}]},{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"118","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"For Patients With Improvement Only: OTE as a Measure of Patient Responsiveness/Satisfaction: Question 2 - Patient's Evaluation of the Importance of the Change in Symptoms","description":"For patients with improvement only, comparison between the 2 cohorts (Compound Sodium Alginate Double Action Chewable Tablets and matching placebo) in OTE as a measure for patient's responsiveness/satisfaction, determined at Visit 3, the end-of-study visit.\n\nQuestion 2 of the OTE addressed how patients perceived the importance of the change of the clinical status on a 7-point scale (from 1 = not important to 7 = extremely important).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"48","spread":null}]},{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"40","spread":null}]},{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"49","spread":null}]},{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"151","spread":null}]},{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"112","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":549},"commonTop":[]}}}